NeuroOne FY2024 product revenue $3.5M (+77%); FY2025 guidance $8-10M (+132-190%)

NEUROONE MEDICAL TECHNOLOGIES Corp

Product revenue FY2024 $3.5M (+77% YoY); net loss $12.3M vs $11.9M prior year.
FY2025 product revenue guidance $8-10M (+132-190%); gross margin 47-51% vs 31% in FY2024.
Received $3M upfront from expanded Zimmer Biomet distribution agreement in Nov 2024; terminated $3M credit facility.
Net loss Q4 $3.3M vs $3.1M; operating expenses down 12% to $3.0M in Q4.
Nasdaq compliance: monitoring bid price until Jan 7, 2025; equity restored above $2.5M after Zimmer payment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.